

**HCAR2 antibody - C-terminal region**  
**Rabbit Polyclonal Antibody**  
**Catalog # AI15030****Specification**

---

**HCAR2 antibody - C-terminal region - Product Information**

Application	WB
Primary Accession	<a href="#">Q8TDS4</a>
Other Accession	<a href="#">NM_177551</a> , <a href="#">NP_808219</a>
Reactivity	Human, Mouse, Rat, Rabbit, Bovine, Guinea Pig
Predicted Host	Human, Mouse, Rat
Clonality	Rabbit
Calculated MW	Polyclonal 42kDa KDa

**HCAR2 antibody - C-terminal region - Additional Information****Gene ID** 338442

**Alias Symbol** **HM74a, HM74b, NIACR1, PUMAG, Puma-g**

**Other Names**  
Hydroxycarboxylic acid receptor 2, G-protein coupled receptor 109A, G-protein coupled receptor HM74A, Niacin receptor 1, Nicotinic acid receptor, HCAR2, GPR109A, HCA2, HM74A, NIACR1

**Format**

Liquid. Purified antibody supplied in 1x PBS buffer with 0.09% (w/v) sodium azide and 2% sucrose.

**Reconstitution & Storage**

Add 50 ul of distilled water. Final anti-HCAR2 antibody concentration is 1 mg/ml in PBS buffer with 2% sucrose. For longer periods of storage, store at 20°C. Avoid repeat freeze-thaw cycles.

**Precautions**

HCAR2 antibody - C-terminal region is for research use only and not for use in diagnostic or therapeutic procedures.

**HCAR2 antibody - C-terminal region - Protein Information****Name** HCAR2**Synonyms** GPR109A, HCA2, HM74A, NIACR1**Function**

Acts as a high affinity receptor for both nicotinic acid (also known as niacin) and (D)-beta-hydroxybutyrate and mediates increased adiponectin secretion and decreased lipolysis through G(i)- protein-mediated inhibition of adenylyl cyclase. This pharmacological effect requires nicotinic acid doses that are much higher than those provided by a normal diet. Mediates nicotinic acid-induced apoptosis in mature neutrophils. Receptor activation by nicotinic acid results in

reduced cAMP levels which may affect activity of cAMP-dependent protein kinase A and phosphorylation of target proteins, leading to neutrophil apoptosis. The rank order of potency for the displacement of nicotinic acid binding is 5-methyl pyrazole-3-carboxylic acid = pyridine-3-acetic acid > acifran > 5-methyl nicotinic acid = acipimox >> nicotinuric acid = nicotinamide.

#### **Cellular Location**

Cell membrane; Multi-pass membrane protein

#### **Tissue Location**


Expression largely restricted to adipose tissue and spleen. Expressed on mature neutrophils but not on immature neutrophils or eosinophils.

### **HCAR2 antibody - C-terminal region - Protocols**

Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

### **HCAR2 antibody - C-terminal region - Images**



WB Suggested Anti-HCAR2 Antibody Titration: 1.0 µg/ml  
Positive Control: MCF7 Whole Cell

### **HCAR2 antibody - C-terminal region - References**

Wise A., et al. J. Biol. Chem. 278:9869-9874(2003).  
Takeda S., et al. FEBS Lett. 520:97-101(2002).  
Suwa M., et al. Submitted (JUL-2001) to the EMBL/GenBank/DDBJ databases.  
Kostylina G., et al. Cell Death Differ. 15:134-142(2008).  
Offermanns S., et al. Pharmacol. Rev. 63:269-290(2011).